Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TTR | P02766 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | BCAT1 | P54687 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | ACSL1 | P33121 | 2/20 | 0.43 |
| ▸ | ACSL6 | Q9UKU0 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494005 | 1.00 | NPSR1 (0.49) | NPSR1TTRLMNABCAT1CYP1A2 | |
| Furobufen SCHEMBL43450 | 0.84 | CYP1A2 (0.58) | NPSR1TTRLMNABCAT1CYP1A2 | |
| Furobufen SCHEMBL30901203 | 0.84 | CYP1A2 (0.58) | NPSR1TTRLMNABCAT1CYP1A2 | |
| SCHEMBL8012440 | 0.80 | BCAT1 (0.46) | TTRLMNABCAT1NPC1RAB9A | |
| SCHEMBL8012438 | 0.80 | BCAT1 (0.46) | TTRLMNABCAT1NPC1RAB9A | |
| Furobufen SCHEMBL10427960 | 0.78 | SMN1; SMN2 (0.65) | NPSR1TTRLMNABCAT1CYP1A2 | |
| SCHEMBL11846734 | 0.77 | NPSR1 (0.60) | NPSR1TTRLMNACYP1A2NPC1 | |
| SCHEMBL6421340 | 0.76 | TTR (0.41) | TTRLMNABCAT1CYP1A2NPC1 | |
| SCHEMBL6421339 | 0.76 | TTR (0.41) | TTRLMNABCAT1CYP1A2NPC1 | |
| SCHEMBL16448159 | 0.76 | TTR (0.58) | TTRLMNABCAT1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100119489-A1 | Stimulation of Pancreatic Beta Cell Proliferation | STOFFEL MARKUS | 2010-05-13 | — | — | US | claimed |
| EP-0828726-B1 | TRICYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER LAMBERT CO (US) | 2001-10-04 | — | — | EP | claimed |
| EP-0828726-A1 | TRICYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-18 | — | — | EP | claimed |
| US-5665764-A | FOR TREATING DISORDERS DEPENDENT UPON TISSUE INVASION BY LEUKOCYTES | WARNER-LAMBERT COMPANY (US) | 1997-09-09 | — | — | US | claimed |
| WO-1996038434-A1 | TRICYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1996-12-05 | — | — | WO | claimed |
| EP-2605013-A1 | Stimulation of pancreatic beta-cell proliferation | THE ROCKEFELLER UNIVERSITY (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20100119489-A1 | Stimulation of Pancreatic Beta Cell Proliferation | STOFFEL MARKUS | 2010-05-13 | — | — | US | disclosed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-5948780-A | ADMINISTERING A METALLOPROTEINASE INHIBITOR | WARNER-LAMBERT COMPANY (US) | 1999-09-07 | — | — | US | disclosed |
| WO-1999032150-A1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| WO-1998026773-A1 | USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING | WARNER-LAMBERT COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| EP-0828726-A1 | TRICYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5665764-A | FOR TREATING DISORDERS DEPENDENT UPON TISSUE INVASION BY LEUKOCYTES | WARNER-LAMBERT COMPANY (US) | 1997-09-09 | — | — | US | disclosed |
| US-5627206-A | TREATING MULTIPLE SCLEROSIS | WARNER-LAMBERT COMPANY (US) | 1997-05-06 | — | — | US | disclosed |
| WO-1996038434-A1 | TRICYCLIC INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176393-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | NPSR1 4183/4885TTR 1627/4885LMNA 1874/4885 |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | NPSR1 4183/4885TTR 1627/4885LMNA 1874/4885 |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | MMP9, TIMP3, MMP3 | NPSR1 4183/4885TTR 1627/4885LMNA 1874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.